Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Materials (30)
- (-) Nuclear Science and Technology (3)
- Biology and Environment (18)
- Clean Energy (12)
- Fuel Cycle Science and Technology (1)
- Fusion and Fission (10)
- Isotopes (3)
- Materials Characterization (1)
- Materials for Computing (3)
- Materials Under Extremes (1)
- National Security (5)
- Neutron Science (9)
- Supercomputing (9)
News Topics
- (-) Biology (3)
- (-) Climate Change (3)
- (-) Fusion (1)
- (-) Isotopes (3)
- (-) Materials Science (10)
- (-) Nuclear Energy (4)
- (-) Physics (9)
- (-) Polymers (3)
- 3-D Printing/Advanced Manufacturing (7)
- Advanced Reactors (2)
- Artificial Intelligence (3)
- Bioenergy (3)
- Biomedical (3)
- Buildings (2)
- Chemical Sciences (16)
- Composites (1)
- Computer Science (3)
- Coronavirus (2)
- Critical Materials (2)
- Cybersecurity (1)
- Decarbonization (4)
- Energy Storage (13)
- Environment (4)
- Exascale Computing (1)
- Frontier (1)
- Grid (2)
- High-Performance Computing (2)
- Machine Learning (1)
- Materials (33)
- Microscopy (5)
- Molten Salt (1)
- Nanotechnology (5)
- National Security (2)
- Net Zero (1)
- Neutron Science (7)
- Partnerships (7)
- Quantum Science (2)
- Renewable Energy (1)
- Security (1)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
- Transportation (2)
Media Contacts
The United Kingdom’s National Nuclear Laboratory and the U.S. Department of Energy’s Oak Ridge National Laboratory have agreed to cooperate on a wide range of nuclear energy research and development efforts that leverage both organizations’ unique expertise and capabilities.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.